The Danish biotech’s recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed ...

CEO Adam Steensberg emphasized 2024 as a transformational year for Zealand Pharma, highlighting significant clinical advancements in its obesity pipeline, particularly with petrelintide and ...

Initiated in December 2024, the Phase 2b ZUPREME-1 trial is designed to evaluate five target doses of petrelintide up to 9 mg over 42 weeks of treatment. Zealand Pharma remains on track to ...

Roche's move for the asset comes shortly after Zealand started the phase 2b ZUPREME-1 trial of petrelintide in people overweight or obese, and ahead of the ZUPREME-2 study in overweight or obese ...

The obesity drug market has experienced a seismic shift in recent years, with Novo Nordisk's (NOV: N) Wegovy (semaglutide) ...

Roche and Zealand Pharma will co-commercialize petrelintide in the U.S. and Europe, sharing profits 50/50. Feel unsure about the market’s next move? Copy trade alerts from Matt Maley—a Wall ...

Per the terms of the agreement, both companies will develop and commercialize petrelintide, Zealand Pharma’s amylin analog, as a standalone therapy and in a fixed-dose combination with Roche’s ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. In the obesity drug universe, the rise of GLP-1 ...

Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight ...

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phase 2b ZUPREME-1 trial is ...